



## Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2016 Investor Update Call

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Ironwood Pharmaceuticals, Inc.](http://www.ironwoodpharma.com) (NASDAQ: IRWD) today announced it will host its fourth quarter and full-year 2016 investor update conference call and webcast at 4:30 p.m. Eastern Time on Tuesday, February 21, 2017. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 59788100. To access the webcast, please visit the Investors section of Ironwood's website at [www.ironwoodpharma.com](http://www.ironwoodpharma.com) at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting February 21, 2017 at approximately 7:30 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on February 28, 2017. To listen to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 59788100. The archived webcast will be available on Ironwood's website for 14 days beginning approximately one hour after the call has completed.

### About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is a commercial biotechnology company focused on creating medicines that make a difference for patients, building value for our fellow shareholders, and empowering our passionate team. We are commercializing two innovative primary care products: linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and lesinurad, which is approved to be taken with a xanthine oxidase inhibitor (XOI) for the treatment of hyperuricemia associated with uncontrolled gout. We are also advancing a pipeline of internally and externally generated innovative product candidates in areas of significant unmet need, including uncontrolled gastroesophageal reflux disease and vascular and fibrotic diseases. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. For more information, please visit [www.ironwoodpharma.com](http://www.ironwoodpharma.com) or [www.twitter.com/ironwoodpharma](https://www.twitter.com/ironwoodpharma); information that may be important to investors will be routinely posted in both these locations.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170207006429/en/>

Ironwood Pharmaceuticals, Inc.  
*Media Relations*  
Trista Morrison, 617-374-5095  
Director, Corporate Communications  
[tmorrison@ironwoodpharma.com](mailto:tmorrison@ironwoodpharma.com)

or  
*Investor Relations*  
Meredith Kaya, 617-374-5082  
Director, Investor Relations  
[mkaya@ironwoodpharma.com](mailto:mkaya@ironwoodpharma.com)

Source: Ironwood Pharmaceuticals, Inc.

News Provided by Acquire Media